Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Helen Thackray Insider Profile
4 Followers
Helen Thackray, SVP Clinical Development, CMO at GlycoMimetics, holds 264.99K shares in BioCryst (Ticker: BCRX), holds 0.00 shares in ImmunoGen (Ticker: IMGN), holds 183.12K shares in GlycoMimetics (Ticker: GLYC).
Helen Thackray has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Helen Thackray holds in companies
Most Profitable Insider Trade
The most profitable trade made by Helen Thackray
Helen Thackray's Trading History
GlycoMimetics
Jan 22, 2021
SVP Clinical Development, CMO
Uninformative Buy
―
$37.54K
BioCryst
Dec 17, 2024
Chief R&D Officer
Uninformative Sell
53.84K
$1.96M
ImmunoGen
Feb 12, 2024
―
Uninformative Sell
―
$0.00
List of latest transactions for each holding click on a transaction to see Helen Thackray's performance on stock
You May Also Like
Helen Thackray insider profile FAQ
What is the percentage of profitable transactions made by Helen Thackray?
The percentage of profitable transactions made by Helen Thackray is ―.
What is the average return per transaction made by Helen Thackray?
The average return per transaction made by Helen Thackray is ―.
What stocks does Helen Thackray hold?
Helen Thackray holds: GLYC, BCRX, IMGN stocks.
What was Helen Thackray’s latest transaction?
Helen Thackray latest transaction was an Uninformative Sell of $53.84K.
What was Helen Thackray's most profitable transaction?
Helen Thackray’s most profitable transaction was an Informative Buy of BCRX stock on May 15, 2024. The return on the trade was 19.60%.
What is Helen Thackray's role in GlycoMimetics?
Helen Thackray's role in GlycoMimetics is SVP Clinical Development, CMO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.